StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Beckman Coulter (Diagnostics & Life Sciences) by Month

Beckman Coulter (Diagnostics & Life Sciences) — FDA 510(k) Clearances

Danaher Beckman Coulter (Diagnostics & Life Sciences): 1 in Sep 2026, down 50.0% from a year earlier.

Latest, Sep 2026
1
Period ended Sep 30, 2026
Change on a year earlier
-50.0%
2 in Sep 2025
History
117 months
Since Feb 2015
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)

Where the Sep 2026 figure comes from

Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Reported in U.S. FDA openFDA Device 510(k) Clearances API.

Monthly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBeckman Coulter (Diagnostics & Life Sciences) — FDA 510(k) ClearancesYear on yearSource
Sep 2026Sep 30, 20261-50.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Aug 2026Aug 31, 20260-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Jul 2026Jul 31, 20260-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Jun 2026Jun 30, 20260-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
May 2026May 31, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Apr 2026Apr 30, 20260–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Mar 2026Mar 31, 202620.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Feb 2026Feb 28, 20261–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Jan 2026Jan 31, 20261–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Dec 2025Dec 31, 20250–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Nov 2025Nov 30, 20251–U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Oct 2025Oct 31, 20250-100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Sep 2025Sep 30, 20252+100.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Aug 2025Aug 31, 20253+200.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Jul 2025Jul 31, 20251-66.7%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Jun 2025Jun 30, 20251-50.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Cite this data

StockData. (2026). Danaher Beckman Coulter (Diagnostics & Life Sciences), monthly Feb 2015–Sep 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-510k-beckman-coulter

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.